Chirag D. Shah

https://assets.montefioreeinstein.org/profiles/images/physphoto/Shah_Chirag_MD_420x504.jpg

First Name

Chirag

Last Name

Shah

NPI

1164629770

Faculty ID

15234

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5732

Visit Type ID

2542

Is Open Scheduling

On

Ali Sadoughi

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/0896c190-56c0-11ec-a12b-63debfbf42ce.jpg

First Name

Ali

Last Name

Sadoughi

NPI

1699933879

Faculty ID

14807

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Ali Sadoughi is Director of Interventional Pulmonology and Bronchoscopy. His clinical expertise is in interventional pulmonology and thoracic oncology, an evolving sub-specialty of pulmonary and critical care medicine. This field focuses on patients with benign and malignant chest diseases.</p>
<p>Dr. Sadoughi performs advanced diagnostic and therapeutic procedures for patients with lung nodules/masses, intra-thoracic lymphadenopathy, pleural diseases, and severe asthma. These include:</p>
<ul>
<li>Sampling of pulmonary lesions; both peripherally and centrally located in the lung; using endobronchial ultrasound (EBUS, both radial and linear array probes) and navigational bronchoscopy</li>
<li>Therapeutic rigid and flexible bronchoscopy on patients with major airway disorders, including tumor de-bulking, airway dilatation and stent placement</li>
<li>Diagnostic and therapeutic procedures on patients with pleural disease and effusion</li>
<li>Therapeutic interventions such as pleurodesis, tunneled pleural catheter and chest tube placement</li>
<li>Bronchial thermoplasty for severe asthma&nbsp;</li>
<li>Endobronchial valve placement for persistent air leak from the lung</li>
</ul>
<p>His other&nbsp;experience is in ultrasonography and echocardiography and their applications in pulmonary and critical care medicine.</p>
<p>Dr. Sadoughi's research interests are in evolution and application of sophisticated and modern technologies for early and minimally invasive diagnosis and treatment of different pulmonary diseases, from lung cancers, to airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure, and pleural diseases. The outcome of his research studies in pulmonary hypertension and interventional pulmonology has been published in high-ranking medical journals and presented in different national conferences.</p>
<h3>Clinical Specialties</h3>
<ul>
<li>Pulmonary Medicine
<ul>
<li>Interventional Pulmonology</li>
<li>Lung Cancer</li>
</ul>
</li>
<li>Critical Care</li>
</ul>
<h3>Board Certification</h3>
<ul>
<li>Pulmonary Disease</li>
<li>Critical Care Medicine</li>
<li>Internal Medicine</li>
</ul>
<h3>Education &amp; Training</h3>
<ul>
<li>Medical School: Shahid Beheshti University of Medical Sciences</li>
<li>Residency: Kingsbrook Jewish Medical Center</li>
<li>Fellowship: Hofstra-North Shore LIJ School of Medicine</li>
<li>Fellowship: Washington University in Saint Louis</li>
</ul>
<h3>Professional Memberships</h3>
<ul>
<li>American Association of Bronchology and Interventional Pulmonology (AABIP), Member</li>
<li>American College of Chest Physicians (ACCP), Member</li>
<li>American Thoracic Society (ATS), Member</li>
<li>International Association for the Study of Lung Cancer&nbsp;(IASLC),&nbsp;Member</li>
</ul>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sadoughi specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.

Elsevier Profile

Selected Publications

<ol>
<li>Bronchomediastinal Fistula From Erosion of Surgical Pledgets Into the Airway, Sadoughi A, Meyers B, Chenna P, Chest. 2015;148:838A. doi:10.1378/chest.2261266</li>
<li>Obstruction of the Trachea with Necrotic Tissue from a Pleomorphic Lung Carcinoma,&nbsp;Sadoughi A, Hyman K, Patel D, Chest. 2014;146:768A. doi:10.1378/chest.1991851.</li>
<li>Diagnosis and Safe Ablation of Endobronchial Hamartoma with Interventional Bronchoscopy,&nbsp;Sadoughi A, Folch E, Majid A. Am J Respir Crit Care Med 189;2014:A4447.</li>
<li>Macrophage migration inhibitory factor mediates hypoxia- induced pulmonary hypertension, Yinzhong Zhang, Arunabh Talwar, Donna Tsang, Annette Bruchfeld, Ali Sadoughi, Maowen Hu, Kennedy Omonuwa, Kai Fan Cheng, Yousef Al-Abed, and Edmund J. Miller, Molecular Medicine, Nov 2011, PMID: 22113497.</li>
<li>Impaired Heart Rate Recovery After Cardio Pulmonary Exercise Testing [CPET] In Patients with Pulmonary Arterial Hypertension, Arunabh Talwar MD, Ali Sadoughi&nbsp; MD,&nbsp; Purvesh&nbsp; Patel MD,&nbsp; Tara George, Donna Tsang, Nina Kohn MS; Chest. 2011;140(4_MeetingAbstracts):723A. doi:10.1378/chest.1119783</li>
<li>A 77-year-old woman with dyspnea and Reynaud phenomenon. Wang J, Sadoughi A, Dedopoulos S, Talwar A, Chest. 2011 Apr;139(4):958-6. PMID: 21467065</li>
<li>Intracranial Pressure Treatment Tailored to Transcranial Doppler-Derived Compliance and Perfusion. Kapinos G, Sadoughi A, Narayan R, oral presentation, November 2013 at the 15th International Conference on Intracranial Pressure and Brain Monitoring, Singapore.</li>
<li>Management of Increased Intracranial Pressure. Sadoughi A, Rybinnik I, Cohen R. The Open Critical Care Medicine Journal, 2013, 6, (Suppl 1: M4) 56-65.</li>
<li>Use of Selective Serotonin Reuptake Inhibitors and Outcomes in Pulmonary Arterial Hypertension, Sadoughi A, Roberts K, Preston I, Lai GP, Mcollister D, Farber HW, Hill NS, Chest. 2013 Apr 4. PMID: 23558791.</li>
<li>Inflammatory Mechanisms in Pulmonary Hypertension, A Sadoughi, Y Zhang, EJ Miller, A Talwar; <em>CML (Current Medical Literature) &ndash; Pulmonary Hypertension </em>2010;1(4):93&ndash;106.</li>
<li>Computed Tomography Angiogram of the Chest as a Valuable Predicting Tool for Pulmonary Arterial Hypertension, A Sadoughi, N Patel, J Wang, N Kohn, R Shah, A Talwar; Chest. 2010;138(4_MeetingAbstracts):357A. doi:10.1378/chest.10559</li>
<li>Arterial Concentration of Macrophage Migration Inhibitory Factor (MIF) increases with exercise in patients with pulmonary Hypertension (PH), A Sadoughi, EJ Miller, A Talwar, presented at FOCIS 2011, Washington, DC.</li>
<li>Utility of Pulmonary Artery Diameter in Computed Tomography of Chest as a screening tool for Pulmonary Arterial Hypertension, A Sadoughi, T Chandak, N Kohn, R Shah, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>Relationship of Pulmonary Arterial Oxygen Saturation with Right Atrial Pressure in Pulmonary Hypertension, T Chandak, A Sadoughi, N Kohn, A Talwar, Presented in ATS Meeting, May 2010.</li>
<li>A case of Portopulmonary Hypertension, Sadoughi A, Mukherji R, Mehra S, Talwar A, The Journal of Respiratory Diseases, September, 2008.</li>
<li>Arteriotomy Closure Device Application Following Percutaneous Coronary Intervention May Prevent Bleeding Complication in Patients with Acute Myocardial Infarction, F. Ikeno, M. Ali Sadoughi, J. Lyons, F. Raissi, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kaneda, A. C. Yeung, M. Rezaee, International J. of Cardiology, April 2007, 117(1), 131-132, PMID:16935367.</li>
<li>The Conversion in Application of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, F. Ikeno, F. Raissi, M. Ali Sadoughi, J.K. Lyons, K. Pourdehmobed, V. Hashemi, S. Emami, H. Kanada, A.C. Yeung, M. Rezaee, International Journal of Cardiology, November 2006, 113(2), 279-280, PMID: 16318883.</li>
<li>Drug-eluting stents alter referral patterns for revascularization in patients with multivessel coronary artery disease, HMO Farouque, Fearon WF, Wu BM, Luna J, Shabari FR, Sadoughi MA, Lee DP, Yeung AC, Heart, Lung, Circulation 2005; 14 Suppl 1: S77, Australia</li>
<li>Changes in the Practice of Percutaneous Coronary Intervention Following the Introduction of Drug Eluting Stents, Raissi F., Sadoughi M.A., Hashemi V., Pourdehmobed K., Farouque O., Lyons J., Emami S., Ikeno F., Kaneda H., Yeung A.C., Rezaee M., TCT (Transcatheter Cardiovascular Therapeutics) meeting 2004, Washington DC, Poster Presentation, 09 / 2004.</li>
</ol>

EMR ID

78160

Biography

<p>Ali Sadoughi, MD, is Director, Interventional Pulmonology and Bronchoscopy and Associate Professor, Medicine at Montefiore Einstein. He specializes in interventional pulmonology, a subspecialty of pulmonary and critical care medicine that uses endoscopy and other minimally invasive tools to diagnose and treat patients with benign and malignant chest diseases.</p><p>After earning his Doctor of Medicine at Shahid Beheshti University of Medical Sciences in Tehran, Iran, Dr. Sadoughi completed an internal medicine residency at Kingsbrook Jewish Medical Center. Following this, he completed a pulmonary and critical care fellowship at Hofstra-North Shore LIJ School of Medicine in 2014 and an interventional pulmonary fellowship at Washington University in 2015.</p><p>Dr. Sadoughi's research interests are in developing and applying advanced technologies for early and minimally invasive diagnosis and treatment of pulmonary diseases. These include lung cancers, airway disorders, pulmonary hypertension, interstitial lung disease, respiratory failure and pleural diseases. His work has been published in journals including <em>Chest</em> and the <em>Journal of Molecular Medicine</em>, and he has made presentations at national and international medical meetings. One of his recent research studies focuses on the development of brachytherapy seeds (DaRT) using alpha radiation for the treatment of lung cancer, sponsored by Alpha Tau Ltd. In another study, he works with an international group of pulmonologists on the role of confocal laser endomicroscopy (CLE) in the diagnosis of different benign and malignant lung diseases. His work related to increased precision and accuracy of biopsy of peripheral lung nodules by intraprocedural 3D scanning in combination with ultrathin bronchoscopy has been published in the <em>Journal of Bronchology and Interventional Pulmonology</em>. Another area of Dr. Sadoughi&rsquo;s research involves the synergy of local therapies such as cryotherapy with immunotherapy in the treatment of lung cancer. He has presented this exciting topic at the American Association of Bronchology and Interventional Pulmonology (AABIP) Conference in 2022.</p><p>Dr. Sadoughi is board certified in interventional pulmonology, pulmonary disease, critical care medicine and internal medicine. He is a member of professional societies such as the American Association of Bronchology and Interventional Pulmonology, the World Association of Bronchology and Interventional Pulmonology, the American College of Chest Physicians, the American Thoracic Society and the International Association for the Study of Lung Cancer. He has contributed his research to the U.S. News, Politico New York and OncLive, and has been an editorial member and reviewer of multiple medical journals.</p>

Is Open Scheduling

On

Michael J. Ross

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ross_Michael_MD_420x504.jpg

First Name

Michael

Last Name

Ross

NPI

1851321368

Faculty ID

15329

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="p1">&nbsp;</p>
<p class="p1">The major focus of research in the Ross laboratory is to identify novel mechanisms of kidney injury occurring in HIV-positive persons and his laboratory uses in vitro and murine models to generate new strategies to prevent and treat kidney diseases. Dr. Ross also works with members of the International Network for Strategic Initiatives in Global HIV Treatment (INSIGHT) to perform research on kidney disease in the context of large international HIV treatment trials.</p>
<p class="p1"><strong><span style="text-decoration: underline;">Ongoing NIH-funded projects:</span></strong></p>
<p class="p1"><strong>Mechanisms by which antiretroviral medications protect kidneys from HIV-induced injury:</strong></p>
<p class="p1">Though combination antiretroviral therapy (cART) is efficacious in preventing and treating HIV-associated nephropathy (HIVAN), the mechanisms by which these medications protect the kidney from the deleterious effects of HIV are poorly understood.&nbsp;&nbsp;We are performing studies using transgenic animal models and molecular and genomic techniques to identify novel pathways by which ART protect the kidneys from HIV.&nbsp;&nbsp;Moreover, we have exciting data suggesting that these medications may protect kidneys from non-viral mediated forms of kidney injury, including diabetic kidney disease.</p>
<p class="p1"><strong>The role of APOL1 polymorphisms in promoting HIV-induced kidney injury:</strong></p>
<p class="p1">Polymorphisms in the APOL1 gene account for most of the excess risk of African-Americans to non-diabetic kidney disease and HIV-associated kidney disease in particular. In our studies, we are using genetically modified human kidney cells to perform innovative proteomic, and genomic studies to identify novel mechanisms by APOL1 genetic variants predispose to HIV-induced kidney injury.&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p><span style="color:black;">Chronic kidney disease, diabetic kidney disease, acute kidney injury, glomerular diseases, cystic kidney diseases, electrolyte disorders, hypertension, HIV and other virus-related kidney diseases.</span></p>

Research Focus

<p><span style="color:black;">The primary focus of Dr. Ross' research is to identify mechanisms by which HIV and immune dysregulation cause kidney disease and to identify new approaches to prevent and treat kidney disease. Dr. Ross is also involved in clinical studies to determine mechanisms of diabetic kidney injury and to test the effectiveness of novel treatments for chronic kidney diseases.</span></p>

Elsevier Profile

Selected Publications

<p><span style="text-decoration: underline;"><strong>Most relevant publicatiion in past 10 years:</strong></span></p>
<p>*Mocroft, A., Wyatt, C., Szczech, L., Neuhaus, J., El-Sadr, W., Tracy, R., Kuller, L., Shlipak, M., Angus, B., Klinker, H., and <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>. Interruption of antiretroviral therapy is associated with increased plasma cystatin C: Results from the SMART Study. <em>AIDS</em>. 23, 71-82. 2009.</p>
<p>*Snyder A, Alsauskas Z, Gong P, Rosenstiel P, Klotman M, Klotman P, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>: FAT10: a novel mediator of Vpr-induced apoptosis in HIV-associated nephropathy. <em>J Virol</em>. 83;11983-11988. 2009.</p>
<p>*Gong, P., Canaan, A., Wang, B., Leventhal, S., Snyder, A., Nair, V., Cohen, C. D., Kretzler, M., D'Agati, V., Weissman, S., and <strong><span style="text-decoration: underline;">Ross, M. J</span></strong>. The ubiquitin-like protein FAT10 mediates NF-kappaB activation. J Am Soc Nephrol. 21:316. 2009.</p>
<p>Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan J, Barley K, He C, Klotman M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Klotman PE. HIV-1 viral protein r induces ERK and caspase-8 dependent apoptosis in renal tubular epithelial cells. <em>AIDS</em>, 24:1107-1119. 2010.</p>
<p>Neuhaus, J., Jacobs, D.R., Baker, J.V., Calmy, A., Duprez, D., La Rosa, A., Kuller, L., Pett, S.L., Ristola, M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Shlipak, M., Tracy, R., and Neaton, J.D. Markers of Inflammation, Coagulation and Renal Function Are Elevated in Adults with HIV Infection. <em>J Infect Dis</em>. 201:1788-1795. 2010.</p>
<p>Chen, P., Chen, B.K., Mosoian, A., Hays, T., <strong><span style="text-decoration: underline;">Ross, M.J</span></strong>., Klotman, P.E., and Klotman, M.E. Virological Synapses Allow HIV-1 Uptake and Gene Expression in Renal Tubular Epithelial Cells. J Am Soc Nephrol. &nbsp;22(3): 496-507. 2011.</p>
<p>Leventhal, J.S., Alsauskas, Z., Snyder, A., Gong, P., Wang, B., D&rsquo;Agati, V., and <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong> Renal HIV Expression Is Unaffected by Serum LPS Levels in an HIV Transgenic Mouse Model of LPS Induced Kidney Injury. <em>PLoS One.</em> <strong>6</strong>:e20688. 2011.</p>
<p>Papeta, N., Kiryluk, K., Patel, A., Sterken, R., Kacak, N., Snyder, H.J., Imus, P.H., Mhatre, A.N., Lawani, A.K., Julian, B.A., Wyatt, R.J., Novak, J., Wyatt, C.M., <strong><span style="text-decoration: underline;">Ross, M.J.</span></strong>, Winston, J.A., Klotman, M.E., Cohen, D.J., Appel, G.B., D&rsquo;Agati, V.D., Klotman, P.E., and Gharavi, A.G. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. <em>J Am Soc Nephrol.</em> 22:1991-1996. 2011.</p>
<p>Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>*, Wyatt CM*: Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS ONE 7:e40245, (*co-senior authors). 2012.</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD: Exposure to Antiretrovirals (ARVs) and Risk of Renal Impairment among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. J Infect Dis 2013.</p>
<p>Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Crum-Cianflone NF: Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med 14:65-76, 2013</p>
<p>Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 1;207(9):1359-69. 2013.</p>
<p>Lucas, G., Cozzi-Lepri, A., Wyatt, C., Post, F., Bormann, A., Crum-Cianflone, N., and <strong><span style="text-decoration: underline;">Ross, M</span></strong>. Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med 15:116-123. PubMed PMID: 24024499. 2014.</p>
<p>Lucas, GM, <strong><span style="text-decoration: underline;">Ross, MJ</span></strong>, Stock, PG, Shlipak, MG, Wyatt, CM, Gupta, SK, Atta, MG, Wools-Kaloustian, KK, Pham, PA, Bruggeman, LA, Lennox, JL, Ray, PE, and Kalayjian, RC. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update By the HIV Medicine Association of the Infectious Diseases Society of America. <em>Clin Infect Dis</em>; 59(9), e96-e138. 2014.</p>
<p>Ryom, L., Mocroft, A., Kirk, O., <strong><span style="text-decoration: underline;">Ross, M</span></strong>., Reiss, P., Fux, C. A., Morlat, P., Moranne, O., Smith, C., El-Sadr, W., Law, M., and Lundgren, J. D. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 28, 187-199. 2014.</p>
<p>Mocroft A, Lundgren J, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events&nbsp; (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study&nbsp; group. A clinically useful risk-score for chronic kidney disease in HIV infection. J Int AIDS Soc ;17(4 Suppl 3):19514.. PMID: 25394023; PMCID: PMC4224906. 2014.</p>
<p>Leventhal, J.S., He, J.C., and <strong><span style="text-decoration: underline;">Ross, M.J</span></strong><span style="text-decoration: underline;">.</span> Autophagy and Immune Response in Kidneys. <em>Semin Nephrol.</em> 34(1):53-61. 2014.</p>
<p><strong><span style="text-decoration: underline;">Ross, M. J.</span></strong> (2014). Advances in the pathogenesis of HIV-associated kidney diseases. <em>Kidney Int.</em> 86, 266-274. 2014.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. PMID: 25826420; PMCID: PMC4380415. 2015.</p>
<p>Wolf T, <strong><span style="text-decoration: underline;">Ross MJ*</span></strong>, and Davenport A. Minimizing risks associated with renal replacement therapy in patients with Ebola Virus Disease. <em>Kidney Int.</em> 2015. 87, 5-7. 2015.</p>
<p>Achhra AC, Mocroft A, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Kidney disease in antiretroviral-na&iuml;ve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med;16 Suppl 1:55-63. PMID: 25711324; PMCID: PMC4341947. 2015.</p>
<p>Mocroft A, Lundgren JD, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 3:e23-32. 2016.</p>
<p>Leventhal JS, Ni J, Osmond M, Lee K, Gusella GL, Salem F, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. Autophagy Limits Endotoxemic Acute Kidney Injury and Alters Renal Tubular Epithelial Cell Cytokine Expression. PLoS One. 11(3):e0150001. 2016.</p>
<p>Ryom, L, Lundgren, JD, <strong><span style="text-decoration: underline;">Ross, M</span></strong>, Kirk, O, Law, M, Morlat, P, Smit, C, Fontas, E, Fux, CA, Hatleberg, CI, de Wit, S, Sabin, CA, Mocroft, A, D:A:D, SG. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. J Infect Dis. PMID: 27485357. 2016.</p>
<p>Ryom L, Mocroft A, Kirk O, Reiss P, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS. 2017 Mar 28. PMID: 28353536.</p>
<p>Nadkarni GN, Wyatt CM, Murphy B, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. APOL1: a case in point for replacing race with genetics. Kidney Int. 2017 Apr;91(4):768-770. PMID: 28314574.</p>
<p>Rednor SJ, <strong>Ross MJ</strong>. Molecular Mechanisms of Injury in HIV-Associated Nephropathy. Front Med (Lausanne). 2018; 5:177. PMID: 29930940 PMCID: PMC5999756</p>
<p><strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Coates PT. Using CRISPR to inactivate endogenous retroviruses in pigs: an important step toward safe xenotransplantation. Kidney Int. 2018; 93:4-6, PMID: 29198467.</p>
<p><strong><span style="text-decoration: underline;">Ross MJ.</span></strong> New Insights into APOL1 and Kidney Disease in African Children and Brazilians Living With End-Stage Kidney Disease. Kidney Int Rep. 2019; 4:908-910 PMC6611947.</p>
<p>Ryom L, Dilling Lundgren J, Reiss P, Kirk O, Law M, <strong><span style="text-decoration: underline;">Ross M</span></strong>, Morlat P, Andreas Fux C, Fontas E, De Wit S, D'Arminio Monforte A, El-Sadr W, Phillips A, Ingrid Hatleberg C, Sabin C, Mocroft A. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2019 Oct 8;220(10):1629-1634. doi: 10.1093/infdis/jiz369. PubMed PMID: 31504669; PubMed Central PMCID: PMC6782100.</p>
<p>Gao X, Rosales A, Karttunen H, Bommana GM, Tandoh B, Yi Z, Habib Z, Agati V, Zhang W, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>. The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms. Sci Rep. 2019 Nov 1;9(1):15857. doi: 10.1038/s41598-019-52278-3. PubMed PMID: 31676833; PubMed Central PMCID: PMC6825220.</p>
<p>Townsend RR, Guarnieri P, Argyropoulos C, Blady S, Boustany-Kari CM, Devalaraja-Narashimha K, Morton L, Mottl AK, Patel U, Palmer M, <strong><span style="text-decoration: underline;">Ross MJ</span></strong>, Sarov-Blat L, Steinbugler K, Susztak K. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. Kidney Int. 2020 Jan;97(1):10-13. doi: 10.1016/j.kint.2019.09.020. PubMed PMID: 31901339.</p>
<div class="citation-text" data-citation-style="ama">Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, <strong><span style="text-decoration: underline;">Ross M,</span></strong> Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M. Covid-19 and Kidney Transplantation. N Engl J Med. 2020 Jun 18;382(25):2475-2477. doi: 10.1056/NEJMc2011117. Epub 2020 Apr 24. PMID: 32329975; PMCID: PMC7200055.</div>

EMR ID

1540

Biography

<p>Dr. Michael Ross received his MD degree at NYU and completed internal medicine residency training at Duke University, followed by Nephrology Fellowship training at the Icahn School of Medicine at Mount Sinai. While he was on the faculty in the Mount Sinai Division of Nephrology from 2001-17, he served as Nephrology Fellowship Program Director from 2004-2015. He became Chief of Nephrology at the James J. Peters VA Medical Center from 2014-2017, where he helped establish the only VA Kidney Transplant Program in the northeastern US. Dr. Ross became Chief of the Division of Nephrology at the Albert Einstein College of Medicine/Montefiore Medical Center in 2017 where he is currently Chief of Nephrology and Professor of Medicine and Developmental and Molecular Biology.&nbsp;</p><p>Dr. Ross has served in several national/international leadership roles for the American Society of Nephrology and other organizations, served as Deputy Editor of Kidney International, and is currently Nephrology Section Editor of the American College of Physicians Medical Knowledge and Self-Assessment Program. Dr. Ross was also the recipient of the 2021 American Society of Nephrology Distinguished Leader Award. The major focus of Dr. Ross&rsquo; research program is to identify novel mechanisms of HIV-induced kidney diseases and other forms of kidney injury. He is also site principal investigator of clinical and translational research studies of diabetic kidney disease and other kidney diseases.&nbsp;<br /></p>

Is Open Scheduling

Off

Orna Rosen

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/52f35570-35f2-11ed-8123-8ffce84a9f6a.jpg

First Name

Orna

Last Name

Rosen

NPI

1205912151

Faculty ID

1126

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3910

Is Open Scheduling

Off

Evelyn M. Rondinel

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/31d12950-3cae-11ec-9e23-c5d5559390c7.jpg

First Name

Evelyn

Last Name

Rondinel

NPI

1821138702

Faculty ID

18003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4488

Is Open Scheduling

Off

Divya B. Reddy

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f08dec40-c946-11ed-8462-993dfb204153.jpg

First Name

Divya

Last Name

Reddy

NPI

1588828370

Faculty ID

14312

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><strong><span style="font-size: 12pt; font-family: Calibri;">Education:</span></strong></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;">Dr. Reddy earned her medical degree from Padmashree Dr. D. Y. Patil Medical College, India. She completed a master's degree in clinical epidemiology from Boston University School of Public Health prior to starting her Internal Medicine Residency training at Boston University Medical Center. Her post-graduate training also included a Fellowship in Pulmonary and Critical Care Medicine from Boston University Medical Center with a particular focus on pulmonary infections and associated lung destruction.&nbsp;&nbsp;</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><strong><span style="font-size: 12pt; font-family: Calibri;">Research Interests:</span></strong></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;">Dr. Reddy has been involved in several patient-oriented research projects in pulmonary infections. As an investigator in the Regional Prospective&nbsp;Observational Research in Tuberculosis (RePORT) cohort in Puducherry and Tamil Nadu, India&nbsp;her work focused on the impact of smoking and biomass fuel use on TB Disease and its treatment outcomes.&nbsp;She is&nbsp;currently developing a database of patients with non-tuberculous mycobacterial infections seen at Montefiore Medical Center in collaboration with the Division of Infectious Diseases. The goal of this project is to better characterize the natural history&nbsp;and clinical outcomes of these infections.&nbsp;&nbsp;She is also involved in the&nbsp;Women&rsquo;s Interagency HIV Study (WIHS) as the Bronx site pulmonologist and co-investigator to assess the impact of HIV on the development of chronic lung diseases.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;"><strong>Clinical Interests:</strong></span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">1. Bronchiectasis &nbsp; &nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">2. Tuberculosis</span></p>
<p class="MsoNormal" style="margin: 0in -67.5pt 0.0001pt 0in; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">3. Nontuberculous Mycobacterial (NTM) Infections &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">4. Obstructive lung diseases &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri; background-color: #fefefe;">5. COVID-19</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">&nbsp;</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><strong><span style="font-size: 12pt; font-family: Calibri;">Board Certification:</span></strong></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman'; background-color: #fefefe;"><span style="font-size: 12pt; font-family: Calibri;">Dr. Reddy is board-certified in Internal Medicine, Pulmonary and Critical Care Medicine and is a<span class="apple-converted-space">&nbsp;</span><span style="border: 1pt none windowtext; padding: 0in;">member of numerous professional societies, including the American Thoracic Society and the Society of Critical Care Medicine.</span></span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Bronchiectasis, Nontuberculous Mycobacterial infections, COPD, Asthma, Interstitial Lung Disease<quillbot-extension-portal></quillbot-extension-portal><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Bronchiectasis, Nontuberculous mycobacterial infections.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; text-align: justify; text-indent: 4.5pt;"><strong><span style="font-family: Calibri;">Original Publications:</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; text-align: justify; text-indent: 4.5pt;"><span style="font-family: Calibri;">&nbsp;</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">1.&nbsp;&nbsp;&nbsp;&nbsp;<strong>Reddy D</strong>, Little F; Glucocorticoid-Resistant Asthma: More than meets the eye;&nbsp;<em>J Asthma</em>&nbsp;December 2013, Vol. 50, No. 10, Pages 1036-1044, PMID 23923995</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">2.&nbsp;&nbsp;&nbsp;&nbsp;<strong>Reddy D</strong>, O&rsquo;Donnell MR, Welter-Frost AM, Coe A, Horsburgh CR. Discordance between Tuberculin Skin Test and Interferon Gamma Release Assay is Associated with Previous Latent Tuberculosis Infection Treatment.&nbsp;<em>Mycobact Dis</em>&nbsp;2016, 6:227. doi: 10.4172/2161-1068.1000227.</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Divya Reddy</strong>, Jacob Walker, Gary Brandeis MD, Matt Russell MD, C Robert Horsburgh Jr, Natasha Hochberg;&nbsp;Latent Tuberculosis Infection Screening Practices in Long-Term Care Facilities<em>;&nbsp;J Am Geriatr Soc</em>, 2017, 65: 1145&ndash;1151. doi:10.1111/jgs.14696, PMID 28467605</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">4.&nbsp; &nbsp; &nbsp;</span><strong style="font-family: Cambria; font-size: 12pt;"><span style="font-family: Calibri;">Divya Reddy</span></strong><span style="font-size: 12pt; font-family: Calibri;">, Yicheng Ma, Subitha Lakshminarayanan, Swaroop Sahu, Laura F. White, Ayiraveetil Reshma, Gautam Roy, Padmini Salgame, Selby Knudsen, Jerrold J. Ellner, C. Robert Horsburgh, Jr., Sonali Sarkar, Natasha S. Hochberg, Severe Undernutrition in Children Affects Tuberculin Skin Test Performance in Southern India. <em>PLoS ONE 16(7): e0250304. https://doi.org/10.1371/journal. pone.0250304, </em></span><span style="font-size: 12pt; font-family: Calibri;">PMID 34270546</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Cambria;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: Cambria;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in -0.25in 0.0001pt 40.5pt; font-size: medium; font-family: Cambria; text-indent: 4.5pt;"><span style="font-family: Calibri;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in -0.25in 0.0001pt 40.5pt; font-size: medium; font-family: Cambria; text-indent: -0.5in;"><strong><span style="font-family: Calibri;">Book Chapters:</span></strong></p>
<p class="MsoNormal" style="margin: 0in -0.25in 0.0001pt 40.5pt; font-size: medium; font-family: Cambria; text-indent: 4.5pt;"><span style="font-family: Calibri;">&nbsp;</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;O&rsquo;Donnell M,&nbsp;<strong>Reddy D</strong>, Saukkonen J; Antimycobacterial agents; 19^th&nbsp;Edition of&nbsp;<em>Harrison&rsquo;s Principles of Internal Medicine</em>, McGraw-Hill Professional, 2015. Volume 2. Chapter 205e, p. 1132-41</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Reddy D</strong>, O&rsquo;Donnell M; Antimycobacterial agents; 20^th&nbsp;Edition of&nbsp;<em>Harrison&rsquo;s Principles of Internal Medicine,&nbsp;</em>McGraw-Hill Professional, 2018. Volume 1. Chapter 176, p. 1270-79</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Reddy D</strong>, Saukkonen J; Hepatoxicity associated with anti-tuberculosis treatment;<strong>&nbsp;</strong>3^rd&nbsp;Edition of&nbsp;<em>Textbook of</em>&nbsp;<em>Tuberculosis and Nontuberculous Mycobacterial Diseases,</em>&nbsp;Jaypee Brothers Medical Publishers, 2019. Chapter 45, p. 637-643</span></p>
<p class="MsoNormalCxSpMiddle" style="margin: 0in -0.25in 0.0001pt 27pt; text-indent: -22.5pt;"><span style="font-family: Calibri;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Divya Reddy</strong>, Jerrold Ellner; Pathogenesis of Tuberculosis; 6^th&nbsp;Edition of&nbsp;<em>Clinical Tuberculosis</em>, CRC Press, 2020. Chapter 4, p. 51-76</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: Calibri;">&nbsp;</span></p>

EMR ID

73329

Biography

<p>Divya Reddy, MD, MPH, is Program Director, Pulmonary and Critical Care Fellowship and Associate Professor, Medicine at Montefiore Einstein. Her clinical focus centers on bronchiectasis, nontuberculous mycobacterial infections, chronic obstructive pulmonary disease (COPD), asthma and interstitial lung disease.</p><p>After earning her Bachelor of Medicine, Bachelor of Surgery at Dr. D.Y. Patil Medical College in Mumbai, India in 2006, Dr. Reddy moved to the United States to continue her medical training, earning her Master of Public Health at Boston University in 2008. She remained there to complete her internal medicine internship in 2009, followed by her internal medicine residency in 2011. Dr. Reddy then completed a pulmonary and critical care fellowship at Boston University in 2014.</p><p>Building on her clinical experience, Dr. Reddy&rsquo;s research is focused on bronchiectasis and nontuberculous mycobacterial infections. She has been principal investigator and co-investigator on several funded research projects, and her work has been published in numerous peer-reviewed journals, book chapters, review articles and abstracts. She has also given national and international invited presentations, and is a reviewer for scientific journals including the <em>Journal of American Geriatric Society</em>, <em>Annals of American Thoracic Society</em> and the <em>Journal of Infectious &amp; Non-Infectious Diseases</em>, among others.</p><p>Dr. Reddy is board certified in Pulmonary Medicine and Critical Care Medicine by the American Board of Internal Medicine. She is a member of the American Thoracic Society, the American College of Chest Physicians and the Association of Pulmonary and Critical Care Medicine Program Directors. In 2014 and 2015, Dr. Reddy received the Potts Memorial Foundation Grant award.</p>

Visit Type ID

2542

Is Open Scheduling

On

Amanda C. Raff

https://assets.montefioreeinstein.org/profiles/images/amanda-raff.jpg

First Name

Amanda

Last Name

Raff

NPI

1952490369

Faculty ID

8749

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">Dr. Raff is a Professor of Medicine and the Associate Chair of Medicine for Undergraduate Medical Education. She has been the Course Director for the Einstein first year medical student Renal System Course since 2007 and the Internal Medicine Clerkship and Acting Internship Director since 2012.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">She a faculty mentor for the student led Step 1 Group near-peer evidence based guidance program and the Internal Medicine Interest Group.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">She has a clinical practice of CKD and ESRD patients and enjoys rounding on the inpatient Renal Consult and Dialysis services.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;">Dr. Raff&rsquo;s contributions in the field of Medical Education include serving as a Case Editor for&nbsp;&nbsp;Aquifer Internal Medicine, contributing author and reviewer for the Clerkship Directors in Internal Medicine (CDIM) curriculum revision and MKSAP 19 Nephrology section committee member.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">She has been recognized for her teaching excellence at Einstein with the Samuel M. Rosen Outstanding Teacher Award for Excellence in Basic Science Teaching, the Harry Eagle Award for Outstanding Basic Science Teaching, the Harry H. Gordon Award for Outstanding Clinical Teaching and membership in the Leo M. Davidoff Society.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria; line-height: 15.6pt;">Dr. Raff received a bachelor's degree in biology from Indiana University and a MD from Albert Einstein College of Medicine. She completed a residency in Internal Medicine at NewYork Presbyterian Hospital and a chief resident year at NYU Downtown Hospital. She returned to Einstein/Montefiore for a Nephrology Fellowship and joined the Einstein Division of Nephrology faculty in 2004.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Autosomal Dominant Polycystic Kidney Disease (ADPKD)<br />Chronic Kidney Disease (CKD)<br />End Stage Kidney Disease (ESKD, ESRD)<br />Acute Kidney Injury (AKI)<br />Glomerular diseases<br />Hypertension<br />Electrolyte Disorders<br />Kidney Stones<br />

Research Focus

<p><span style="color:black;">&nbsp;</span></p>

Elsevier Profile

Selected Publications

<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">1.&nbsp;</span><span style="font-size: 12pt; font-family: Cambria; color: #212121;">Fitz M, Adams W, Haist S, Hauer K, Ross P,&nbsp;<strong>Raff A</strong>, Agarwal G, Vu T, Appelbaum J, Lang V, Miller C, Grum C and the Clerkship Directors in Internal Medicine &ndash; National Board of Medical Examiners EXPRESS Study Group. Which Internal Medicine Clerkship Characteristics Are Associated With Students' Performance on the NBME Medicine Subject Exam? A Multi-Institutional Analysis.&nbsp;<em>Acad Med</em>. 2020;10.1097/ACM.0000000000003322 [published online ahead of print, 2020 Mar 17].&nbsp;</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria; color: #212121;">2.&nbsp;</span><span style="font-size: 12pt; font-family: Cambria;">Brien K (Author), Calvo L (Associate editor),&nbsp;<strong>Raff A</strong>&nbsp;(Case editor).&nbsp;<em>Aquifer Internal Medicine Case 33: 49-year-old woman with confusion</em>. 2019&nbsp;</span><u><span style="font-size: 12pt; font-family: Cambria; color: #3366ff;">https://www.aquifer.org</span></u></p&gt;
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria; color: #212121;">3.&nbsp;</span><span style="font-size: 12pt; font-family: Cambria;">Khan M, Gil N, Lin W, Fiter R, Kenawy D, Burton W,&nbsp;<strong>Raff A</strong>.&nbsp;&nbsp;The impact of Step 1 scores on medical students&rsquo; residency specialty choice.&nbsp;<em>Med Sci Educ.</em>&nbsp;28(4): 699-705. 2018.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">4.&nbsp;Ludwig A,&nbsp;<strong>Raff A</strong>, Lin J, Schoenbaum E. Group Observed Structured Encounter (GOSCE) for third year medical students improves self-assessment of clinical communication.&nbsp;<em>Medical Teacher</em>&nbsp;39(9): 931-5.&nbsp;2017.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">5.&nbsp;Golestaneh L, Neugarten J, Southern W, Kargoli F,&nbsp;<strong>Raff A</strong>.&nbsp;&nbsp;Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative.&nbsp;<em>Int Urol Nephrol</em>&nbsp;49(3): 491-7. 2017</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">6.&nbsp;Czapka M,&nbsp;<strong>Raff A</strong>, Risley M.&nbsp;&nbsp;Safe Transitions: An active learning module for discharge summaries and interprofessional care.&nbsp;<em>MedEdPORTAL&nbsp;iCollaborative</em>. 2017</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">7.&nbsp;Tanenbaum, E, Johnson J, Jordan, E, Cottral J, Tenore C, Burton W, McGinn A<strong>, Raff A</strong>.&nbsp;&nbsp;An effective evidence-based student run near-peer support group for the USMLE Step 1 Exam.&nbsp;&nbsp;<em>Med Sci Educ</em>. 26(4): 691-9. 2016</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">8.&nbsp;Ludwig A, Lee R, Parish S,&nbsp;<strong>Raff A</strong>. Four-station group observed structured clinical encounter for formative assessment of communication skills for internal medicine clerks.&nbsp;<em>MedEdPORTAL Publications</em>. 12:10444. 2016&nbsp;</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">9.&nbsp;Chen W, Melamed M, Hostetter T, Bauer C,&nbsp;<strong>Raff A</strong>, Almudevar A, Lalonde A, Messing S, Abramowitz M.&nbsp;&nbsp;Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study.&nbsp;&nbsp;<em>BMC Nephrol</em>. 17(1): 114. doi: 10.1186/s12882-016-0331-6. 2016</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">10.&nbsp;Jion Y,&nbsp;<strong>Raff A</strong>, Grosberg B, Evans R.&nbsp;&nbsp;The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension.&nbsp;&nbsp;<em>Headache</em>. 55(1): 161-6. 2015</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">11. Jion Y,&nbsp;<strong>Raff A</strong>, Grosberg B, Evans R.&nbsp;&nbsp;Topiramate and nephrolithiasis: a response.&nbsp;&nbsp;<em>Headache</em>. 55(5): 710-2. 2015</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">12.&nbsp;Abramowitz, M, Melamed M, Bauer C,&nbsp;<strong>Raff A</strong>, Hostetter T.&nbsp;&nbsp;Effects of oral sodium bicarbonate in patients with CKD.&nbsp;&nbsp;<em>Clin J Am Soc Nephrol</em>. 8(5): 714-20. 2013</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">13. Berman N, Lectura M, Thurman J, Reinecke J,&nbsp;<strong>Raff A</strong>, Melamed M, Quan Z, Evans T, Meyer T, Hostetter T.&nbsp;&nbsp;A zebrafish model for uremic toxicity: role of the complement pathway.&nbsp;&nbsp;<em>Blood Purif</em>. 35(4): 265-9. 2013</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">14.&nbsp;Bomback A,&nbsp;<strong>Raff A</strong>.&nbsp;&nbsp;Olfactory function in dialysis patients: a potential key to understanding the uremic state.&nbsp;&nbsp;<em>Kidney Int</em>.&nbsp;&nbsp;80(8): 803-5.&nbsp;&nbsp;2011</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">15.&nbsp;Ponda M, Quan Z, Melamed M,&nbsp;<strong>Raff A</strong>, Meyer T, Hostetter T.&nbsp;&nbsp;&nbsp;Methylamine clearance by haemodialysis is low.&nbsp;&nbsp;<em>Nephrol Dial Transplant</em>.&nbsp;&nbsp;25(5): 1608-13. 2010</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">16.&nbsp;<strong>Raff A</strong>,&nbsp;&nbsp;Lieu S, Melamed M, Quan Z, Ponda M, Meyer T, Hostetter T.&nbsp;&nbsp;Relationship of Impaired Olfactory Function in ESRD to Malnutrition and Retained Uremic Molecules.&nbsp;<em>Am J Kidney Dis</em>.&nbsp;&nbsp;52(1): 102-10.&nbsp;&nbsp;2008</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">17.&nbsp;<strong>Raff A</strong>, Meyer T, Hostetter T.&nbsp;&nbsp;New Insights into uremic toxicity.&nbsp;&nbsp;<em>Curr Opin Nephrol Hypertens</em>.&nbsp;&nbsp;17(6): 560-5.&nbsp;&nbsp;2008</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">18.&nbsp;Susztak K,&nbsp;<strong>Raff A</strong>, Schiffer M, Bottinger E.&nbsp;&nbsp;Glucose &ndash; induced&nbsp;&nbsp;&nbsp;reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.&nbsp;<em>Diabetes</em>. 55(1): 225-33.&nbsp;&nbsp;2006</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">19.&nbsp;Schiffer M. Susztak K, Ranalletta M,&nbsp;<strong>Raff A</strong>, Bottinger E, Charron M.&nbsp;&nbsp;Localization of the GLUT8 transporter in murine kidney and regulation in vivo in non-diabetic and diabetic conditions.&nbsp;&nbsp;<em>Am J Physiol Renal Physiol</em>, 289(1): F186-193.&nbsp;&nbsp;2005</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">20.&nbsp;<strong>Raff A</strong>, Hebert T, Pullman J, Coco M.&nbsp;&nbsp;Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted?&nbsp;&nbsp;<em>Clinical Nephrology</em>, 63(5): 375-380.&nbsp;&nbsp;2005</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">21.&nbsp;Spector M,&nbsp;<strong>Raff A</strong>, DeSilva H, Lee K, Osley M.&nbsp;&nbsp;Hir1p and Hir2p function as transcriptional corepressors to regulate histone gene transcription in&nbsp;<em>Saccharomyces cerevisiae&nbsp;</em>cell cycle.&nbsp;<em>&nbsp;Molecular and Cellular Biology</em>, 17(2):&nbsp;&nbsp;545-552.&nbsp;&nbsp;1997</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">22.&nbsp;Recht J, Dunn B,&nbsp;<strong>Raff A</strong>, Osley M.&nbsp;&nbsp;Functional analysis of histone H2A and H2B in transcriptional repression in&nbsp;<em>Saccharomyces cerevisiae. Molecular and Cellular Biology</em>, 16(6):&nbsp;&nbsp;2545-2553<em>.</em>&nbsp;&nbsp;1996</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 10pt; font-family: 'Times New Roman';"><span style="font-size: 12pt; font-family: Cambria;">23.&nbsp;Kopczynski J,&nbsp;<strong>Raff A</strong>, Bonner J.&nbsp;&nbsp;Translational readthrough at nonsense mutations in the&nbsp;<em>HSF1</em>&nbsp;gene of&nbsp;<em>Saccharomyces cerevisiae.&nbsp;</em>&nbsp;<em>Molecular and General Genetics</em>, 234: 369-378.&nbsp;&nbsp;1992</span></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: Cambria;"><span style="font-family: 'Times New Roman';">&nbsp;</span></p>

EMR ID

4469

Biography

<p>Amanda C. Raff, MD, is Attending Physician, Professor and Associate Chair of Medicine for Undergraduate Medical Education at Montefiore-Einstein. She is also the co-director of the Montefiore-Einstein Autosomal Dominant Polycystic Kidney Disease Program. Dr. Raff&rsquo;s clinical focus is on dialysis and the treatment of patients with chronic kidney disease and end stage kidney disease.</p><p>After earning her Bachelor of Science in biology at Indiana University, Dr. Raff completed her Doctor of Medicine at Albert Einstein College of Medicine, earning her degree in 1998.&nbsp; Her postdoctoral training began at New York Presbyterian Hospital with an internship and residency in internal medicine from 1998 through 2001. She was assistant chief resident at Memorial Sloan Kettering Cancer Center in 2000 and chief resident at New York University Downtown Hospital from 2001 to 2002. She then returned to Montefiore-Einstein to complete a two-year fellowship in nephrology in 2004.</p><p>Dr. Raff&rsquo;s research focuses on medical education. She has been the Course Director for the Einstein medical student Renal Course since 2007 and the Internal Medicine Clerkship and Acting Internship Director since 2012. Dr. Raff&rsquo;s contributions in the field of Medical Education include serving as a Nephrology section committee member for the American College of Physicians&rsquo; Medical Knowledge Self-Assessment Program (MKSAP) 19 and 20 as well as prior work as a Case Editor for Aquifer Internal Medicine and contributing author and reviewer for the Clerkship Directors in Internal Medicine (CDIM) curriculum revision.</p><p>An enthusiastic medical educator, Dr. Raff has received several awards for her teaching and in 2010 was inducted into the Leo M. Davidoff Society for outstanding achievement in the teaching of medical students. She is board certified and is a member the American Society of Nephrology and a fellow of the American College of Physicians.</p>

Visit Type ID

2541

Is Open Scheduling

On

Cindy T. Pynadath

https://assets.montefioreeinstein.org/profiles/images/physphoto/Pynadath_Cindy_DO_420x504.jpg

First Name

Cindy

Last Name

Pynadath

NPI

1205062460

Faculty ID

16837

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Kidney and Pancreas Transplantation

Research Focus

Dr. Pynadath&rsquo;s current research interest in Transplant Medicine explores its connection to infectious disease and mineral bone and metabolic disorders, as well as the clinical outcomes in kidney transplant.&nbsp; Her work collaborations have been published in reputed journals, as well as presented at national and international transplant conferences.&nbsp;&nbsp;

Elsevier Profile

EMR ID

7261

Biography

<p>Cindy T. Pynadath, DO, is a Transplant Nephrologist and Assistant Professor, Medicine at Montefiore Einstein. Her clinical focus centers on kidney and pancreas transplantation.</p><p>After obtaining her Bachelor of Science in integrated life sciences from Kent State University in 2005, Dr. Pynadath earned her Doctor of Osteopathic Medicine at Ohio University College of Osteopathic Medicine in 2009. She then completed her internal medicine residency at the Cleveland Clinic Foundation in 2012 before completing a nephrology fellowship at University Hospitals Case Medical Center in 2014. Following this, Dr. Pynadath completed a transplant nephrology fellowship at the same institution in 2015.</p><p>Dr. Pynadath&rsquo;s current research in transplant medicine explores its connection to infectious disease and mineral bone and metabolic disorders, as well as the clinical outcomes in kidney transplantation. Her work collaborations have been published in a number of reputed journals, as well as presented at national and international transplant conferences.</p><p>Dr. Pynadath is board certified by the American Board of Internal Medicine. She is a member of multiple professional associations including the American Society of Transplantation (AST) and the American Society of Nephrology (ASN). She is a past recipient of the Caregiver Celebrations Appreciation Award for exemplary clinical and patient care from the Cleveland Clinic Foundation.</p>

Is Open Scheduling

Off

David J. Prezant

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4db93d60-5bd2-11ef-9c26-99fb988c3389.jpg

First Name

David

Last Name

Prezant

NPI

1184713489

Faculty ID

2422

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. David Prezant is the Chief Medical Officer at the Office of Medical Affairs for the Fire Department of the City of New York (FDNY). Dr. Prezant directs all medical protocol development for both day-to-day operations and homeland security issues. He is also Co-Director of the FDNY World Trade Center Medical Monitoring Program and the Senior Pulmonary Consultant for FDNY.</p>

<p>Dr. Prezant is a member of the Institute of Medicine's Committee on Personal Protective Equipment in the Workplace, the National Fire Protection Association's Health and Safety Committee, and the International Association of Firefighters Redmond Medical Advisory Board. He is a Professor of Medicine at the Albert Einstein College of Medicine; Director of Albert Einstein Medical School's Pulmonary Course for medical students and the Research Director for their Unified Pulmonary Division.</p>

<p>Dr. Prezant responded on 9/11/01 to the World Trade Center and was present during the collapse and its aftermath. Since that day, he and Dr. Kelly (FDNY's Chief Medical Officer at the Bureau of Health Services) have initiated a multi-million dollar medical monitoring and treatment program for FDNY firefighters funded by FDNY, the Centers for Disease Control and Prevention (CDC) and the National Institute for Occupational Safety and Health (NIOSH).</p>

<p>Dr. Prezant is the Principal Investigator for the FDNY Data Coordinating Center for the WTC Medical Monitoring Program and is on the Steering Committee for the WTC Medical Monitoring Program. He served as a member of the EPA WTC Technical Advisory Committee, the NYC Dept of Health WTC Registry Scientific Advisory Board, the NYS Governor's WTC panel and the NYC Mayor's medical advisory board.</p>

<p>Dr. Prezant has written extensively on pulmonary physiology, firefighter health and safety and since 9/11 on the health impact of World Trade Center Collapse on NYC Firefighters and EMS rescue workers. His group was the first to describe WTC Cough Syndrome (New England Journal of Medicine 2002) and has published extensively on this subject in the CDC MMWR, American Journal of Respiratory and Critical Care Medicine, Chest and Environmental Health Perspectives.</p>

<p>His major research interest is in determining the mechanisms responsible for accelerated decline in longitudinal pulmonary function and/or airway hyperreactivity in firefighters after WTC exposure. Other interests are in determining the mechanisms responsible for the increased incidence of sarcoidosis in firefighters after WTC exposure.</p>

<p><strong>Clinical Specialty Areas</strong></p>

<ul>
<li>environmental and occupational lung disease</li>

<li>firefighters respiratory disease</li>

<li>disaster medicine</li>

<li>pulmonary embolism</li>

<li>general pulmonary medicine</li>
</ul>

<p><strong>More</strong></p>

<p><a href="/medicine/pulmonarymedicine/pulmonary_about.aspx?id=14538">Seven Years Later, a Cough and a Covenant</a> (September 10, 2008)</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol>
<li>World Trade Center site. N Eng J Med 2002;347:806-15.</li>

<li>Banauch GI, McLaughlin M, Hirschhorn R, Corrigan M, Kelly KJ, Prezant DJ. Injuries and Illnesses among New York City Fire Department rescue workers after responding to the World Trade Center Attacks. MMWR 2002;51:1-5.</li>

<li>Prezant DJ, Kelly KJ, Jackson B, Peterson D, Feldman D, Baron S, Mueller CA, Bernard B, Lushniak B, Smith L, BerryAnn R, Hoffman B. Use of respiratory protection among responders at the World Trade Center Site, New York City, September 2001. MMWR 2002;51:6-8.</li>

<li>Rom WN, Weiden M, Garcia R, Ting AY, Vathesatogkit P, Tse DB, McGuinness G, Roggli V, Prezant DJ. Acute eosinophilic pneumonia in a New York City firefighter exposed to world trade center dust. Am. J. Resp. Crit. Care Med. 2002;166:797-800.</li>

<li>Banauch GI, Alleyne D, Sanchez R, Olender K, Weiden M, Kelly KJ, and PREZANT DJ. Persistent bronchial hyperreactivity in New York City firefighters and rescue workers following collapse of World Trade Center. Am. J. Resp. Crit. Care Med. 2003; 168:54-62.</li>

<li>Edelman P, Osterloh J, Pirkle J, Grainger J, Jones R, Blount B, Calafat A, Turner W, Caudill S, Feldman DM, Baron S, Bernard BP, Lushniak BD, Kelly KJ, PREZANT DJ. Biomonitoring of chemical exposure among New York City firefighters responding to the World Trade Center fire and collapse. Environ Health Perspect, 2003; 111:1906-1911.</li>

<li>Feldman DM, Baron S, Mueller CA, Bernard BP, Lushniak BD, Kelly KJ, PREZANT DJ. Initial symptoms, respiratory function and respirator use in New York City firefighters responding to the World Trade Center (WTC) disaster. Chest 2004;125:1256-64.</li>

<li>World Trade Center dust. Environ Health Perspect, 2004; 112:1564-1569.</li>

<li>Banauch GI, Dhala A, Alleyne D, Alva R, Santhyadka G, Krasko A, Weiden M, Kelly KJ, Prezant DJ. Bronchial hyperreactivity and other inhalation lung injuries in rescue/recovery workers after the World Trade Center collapse. Crit Care Med. 2005;33:S102-S106.</li>

<li>World Trade Center site. Curr Opin Pulm Med 2005; 11:160-8.</li>

<li>Paul Greene, Dianne Kane, Grace Christ, Sallie Lynch and Malachy Corrigan. FDNY crisis counseling: innovative responses to 9/11 firefighters, families, and communities. Published 2005.A textbook in counseling at FDNY after WTC.</li>

<li>Bars MP, Banauch GI, Appel DW, Andreaci M, Mouren P, Kelly KJ, Prezant DJ. Tobacco Free with FDNY: The New York City Fire Department World Trade Center Tobacco Cessation Study. Chest 2006; 129:979-987.</li>

<li>World Trade Center exposure in the New York City Fire Department. Am. J. Respir. Crit. Care Med. 2006; 174:312-319.</li>

<li>Friedman S, Cone J, Eros-Sarnyai M, Prezant D,m Szeinuk J, Clark N, Milek D, Levin S, Gillio R. Clinical guidelines for adults exposed to World Trade Center Disaster (Respiratory and Mental Health). City Health Info (CHI), NYC Department of Health and Mental Hygiene. September 2006</li>

<li>Lioy PJ, Pellizzari E, and Prezant DJ. Understanding and learning from the WTC Aftermath and its affect on health through Human Exposure Science. Environ. Science Technology. November 15, 2006 ; 6876-6885.</li>

<li>Izbicki G, Chavko R, Banauch GI, Weiden M, Berger K, Kelly KJ, Aldrich TK and Prezant DJ. World Trade Center Sarcoid-like Granulomatous Pulmonary Disease in New York City Fire Department Rescue Workers. CHEST (In press)</li>

<li>Izbicki G, Chavko R, Banauch GI, Weiden M, Berger K, Kelly KJ, Hall C, Aldrich TK and Prezant DJ.&#160; World Trade Center Sarcoid-like Granulomatous Pulmonary Disease in New York City Fire Department Rescue Workers.&#160; Chest, 2007;131:1414-1423</li>

<li>Weiden M, Banauch G, Kelly KJ, and Prezant DJ. Environmental and Occupational Medicine. Firefighters Health and Health Effects of the World Trade Center Collapse. Pgs 477-490. 4th Edition, Edited by Rom WN and Markowitz S. Lippincott-Raven Inc. Philadelphia, 2007.</li>

<li>Alvarez J, Rosen C, Davis K, Smith G, Corrigan M. Stay Connected : psychological services for retired firefighters after 11 September 2001.&#160; PreHospital Disaster Med. 2007 ;22 :49-54.</li>

<li>Menendez AM, Molloy J., Magaldi MC. Health responses of New York City firefighter spouses and their families post-September 11, 2001 terrorist attacks.&#160; Issues Ment Health Nurs. 2006; 27:905-17.</li>

<li>Kelly KJ, Niles J, McLaughlin MT, Carrol S, Corrigan M, Al-Othman F, and Prezant DJ.&#160; World Trade Center health Impacts on FDNY Rescue Workers - a six year assessment, September 2001 to 2007.&#160; Fire Department of the City of New York, October 2007. Available on-line at: <a href="http://www.nyc.gov/html/om/pdf/2007/wtc_health_impacts_on_fdny_rescue_w…; target="_blank">http://www.nyc.gov/html/om/pdf/2007/wtc_health_impacts_on_fdny_rescue_w…;

<li>Prezant DJ. WTC Cough Syndrome and its Treatment. Lung. 2008 ; 186 :94S-102S.</li>

<li>Banauch GI, Izbicki G, Chavko R, Christodoulou V, Weiden MD, Webber MP, Cohen HW, Gustave J, Aldrich TK, Kelly KJ, and Prezant DJ. Trial of Prophylactic Inhaled Steroids to Prevent or Reduce Pulmonary Function Decline, Pulmonary Symptoms and Airway Hyperreactivity in Firefighters at the World Trade Center Site. Disaster Medicine and Public Health Preparedness 2008; 2:33-39.</li>

<li>Prezant DJ, Levin S, Kelly KJ, Aldrich TK.&#160; Upper and Lower Respiratory Diseases after Occupational and Environmental Disasters.&#160; Mt. Sinai Medical Journal (In Press).&#160;&#160;&#160;&#160;&#160;</li>
</ol>

<p>&#160;</p>

EMR ID

3430

Is Open Scheduling

Off

Kenneth L. Pinsker

https://assets.montefioreeinstein.org/profiles/images/physphoto/Pinsker_Kenneth_MD_420x504.jpg

First Name

Kenneth

Last Name

Pinsker

NPI

1306936273

Faculty ID

3368

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kenneth Pinsker is Professor Emeritus of Medicine at Einstein and an attending physician at Montefiore. He is the former Chief of the Pulmonary Service at the Moses Division and the former Director of the Pulmonary Intensive Care Unit. He is currently a preceptor in the Pulmonary Clinic and makes teaching rounds on the consultation service.</p>
<p><strong>Clinical Specialty Areas</strong></p>
<ul>
<li>pulmonary function</li>
<li>bronchoscopy</li>
<li>pleural disease</li>
<li>general pulmonary medicine</li>
</ul>
<p><strong>Academic and Research Interests </strong></p>
<ul>
<li>lung transplantation</li>
<li>tuberculosis</li>
<li>respiratory failure</li>
<li>World-Trade-Center-related pulmonary disease</li>
<li>history of pulmonary medicine</li>
</ul>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

3427

Is Open Scheduling

Off